Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

Deepa Jagadeesh, Silvana Novelli, Stefano Luminari, Michal Taszner, Michele Merli, Yingzxin Xu, Siddhesh Kamat, Liza Mastikhina, Srikanth Ambati, Jenny Chen, Keith Chan, Shannon Cope, Sam Keeping, Clyde Caisip, Hesham Mohamed, Aafia Chaudhry, James Harnett, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 7803.

https://doi.org/10.1182/blood-2024-200865

Published: 2024

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)

Jenny M.H. Chen, Ina Zhang, James J. Wu, Sally W. Wade, Ana Nunes, Weimin Peng, Julia T. Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal D. Shah

Blood (2023) 142 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2023-177741

Published: 2023

Journal Articles

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Blood (2022) 140 (Supplement 1): 10296–10299.

https://doi.org/10.1182/blood-2022-162638

Published: 2022